Tofogliflozin hydrate

Overview

Tofogliflozin hydrate (CSG-452 hydrate) is a potent and highly specific sodium/glucose cotransporter 2 ( SGLT2 ) inhibitor with an IC 50 of 2.9 nM and K i values of 2.9 nM, 14.9 nM, and 6.4 nM for human, rat, and mouse SGLT2 . Tofogliflozin partially inhibits high glucose-induced reactive oxyen species (ROS) generation in tubular cells.

Application

Products | Products > Disease Areas > Coronavirus Infection | Products > Disease Areas > Lipid Metabolism | Products > Disease Areas > Glucose Metabolism | Products > Disease Areas > SARS-CoV-2 Infection | Products > Disease Areas > Obesity | Products > Disease Areas > Infection | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Signaling Pathways > Membrane Transporter/Ion Channel | Products > Signaling Pathways > NF-κB | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Metabolic Disease | Products > Signaling Pathways > SGLT | Products > Signaling Pathways > Reactive Oxygen Species (ROS)

Product Information

• Catalog No.: HY-13413
• CAS No.: 1201913-82-7
• Molecular Formula: C22H28O7
• Molecular Weight: 404.45
• Purity: 98.38%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 2.5 mg/mL (6.18 mM); Clear solution
• Availability: In-stock

Source

Original product source